162 related articles for article (PubMed ID: 37269344)
1. The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
LoRusso P; Yamamoto N; Patel MR; Laurie SA; Bauer TM; Geng J; Davenport T; Teufel M; Li J; Lahmar M; Gounder MM
Cancer Discov; 2023 Aug; 13(8):1802-1813. PubMed ID: 37269344
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Yamamoto N; Tolcher A; Hafez N; Lugowska I; Ramlau R; Macarulla T; Geng J; Li J; Teufel M; Märten A; LoRusso P
Onco Targets Ther; 2024; 17():267-280. PubMed ID: 38567193
[TBL] [Abstract][Full Text] [Related]
3. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
Ray-Coquard I; Blay JY; Italiano A; Le Cesne A; Penel N; Zhi J; Heil F; Rueger R; Graves B; Ding M; Geho D; Middleton SA; Vassilev LT; Nichols GL; Bui BN
Lancet Oncol; 2012 Nov; 13(11):1133-40. PubMed ID: 23084521
[TBL] [Abstract][Full Text] [Related]
4. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Yoo C; Lamarca A; Choi HJ; Vogel A; Pishvaian MJ; Goyal L; Ueno M; Märten A; Teufel M; Geng L; Morizane C
Future Oncol; 2024 Jan; ():. PubMed ID: 38214149
[TBL] [Abstract][Full Text] [Related]
5. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Gluck WL; Gounder MM; Frank R; Eskens F; Blay JY; Cassier PA; Soria JC; Chawla S; de Weger V; Wagner AJ; Siegel D; De Vos F; Rasmussen E; Henary HA
Invest New Drugs; 2020 Jun; 38(3):831-843. PubMed ID: 31359240
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
11. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR; Bauer S; Suarez C; Lin CC; Quek R; Hütter-Krönke ML; Cubedo R; Ferretti S; Guerreiro N; Jullion A; Orlando EJ; Clementi G; Sand Dejmek J; Halilovic E; Fabre C; Blay JY; Italiano A
Clin Cancer Res; 2022 Mar; 28(6):1087-1097. PubMed ID: 34921024
[TBL] [Abstract][Full Text] [Related]
12. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM; Bauer TM; Schwartz GK; Weise AM; LoRusso P; Kumar P; Tao B; Hong Y; Patel P; Lu Y; Lesegretain A; Tirunagaru VG; Xu F; Doebele RC; Hong DS
J Clin Oncol; 2023 Mar; 41(9):1714-1724. PubMed ID: 36669146
[TBL] [Abstract][Full Text] [Related]
13. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.
Wagner AJ; Banerji U; Mahipal A; Somaiah N; Hirsch H; Fancourt C; Johnson-Levonas AO; Lam R; Meister AK; Russo G; Knox CD; Rose S; Hong DS
J Clin Oncol; 2017 Apr; 35(12):1304-1311. PubMed ID: 28240971
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
[TBL] [Abstract][Full Text] [Related]
18. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
19. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations.
Heymach J; Opdam F; Barve M; Gibson N; Sadrolhefazi B; Serra J; Yamamoto N
Clin Lung Cancer; 2023 Mar; 24(2):e65-e68. PubMed ID: 36528522
[TBL] [Abstract][Full Text] [Related]
20. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
